Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Analysis of Variables Predicting Pathological Complete Response and Immune Related Adverse Events in Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Immunotherapy With Chemotherapy - A Prospective Cohort Study

NCT06250829 is registered in ClinicalTrials.gov with London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's as lead sponsor.

NCT NCT06250829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06250829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Analysis of Variables Predicting Pathological Complete Response and Immune Related Adverse Events in Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Immunotherapy With Chemotherapy - A Prospective Cohort Study
Lead sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase
Observational
Overall status
Unknown status
Start date
October 12, 2023
Completion date
May 30, 2025
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer stage ib (resectable), non-small cell lung cancer stage ii (resectable), non-small cell lung cancer stage Ⅲa (resectable)